PRINCETON, N.J. and MOUNTAIN VIEW, Calif., July 12, 2017 /PRNewswire/ -- Novo Nordisk and Glooko have announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes. The C4C mobile app marries Novo Nordisk's extensive knowledge of diabetes and personalized patient support with Glooko's digital platform and data analytics expertise. This is the first jointly developed product from the two companies since announcing their collaboration in January 2017.
"For over 90 years, Novo Nordisk has continued to develop innovative diabetes medicines and devices. In today's environment, in order to truly improve the prospects of the 29 million people with diabetes in the US, we must aspire towards leadership in digital health that complements our research and development expertise," said David Moore, Senior VP, Marketing for Novo Nordisk Inc. "That was the catalyst to our partnership with Glooko as well as IBM Watson Health and this milestone is just the beginning. Our companies share a common vision of empowering patients with ever improving digital health solutions and we are excited about our combined capabilities and what that can do for improving diabetes treatment."
Beyond the launch of the C4C app, Novo Nordisk is working with Glooko to enhance its Digital Health Platform – a diabetes management system used to store and analyze data and deliver real-time feedback to people with diabetes and their caregivers. In time, this will contribute to Novo Nordisk's ability to provide concrete guidance to patients and healthcare professionals and also demonstrate the cost effectiveness of treatments to healthcare systems.
About the Cornerstones4Care Powered by Glooko App
The modular app concept will initially enable people with diabetes to easily measure and track their blood glucose, activity and meals all in one place, and serve as the framework for additional jointly-developed digital tools from Novo Nordisk and Glooko. The C4C App uses Glooko's cutting-edge technology to sync a user's blood glucose and activity data from the majority of currently available diabetes and exercise devices. It also identifies pertinent trends to aid in understanding the factors that impact blood glucose levels, and includes relevant content and resources exclusively selected from Cornerstones4Care, the personalized support program for people with diabetes (Cornerstones4Care.com). The integrated offering is intended to help people learn how to better manage diabetes through their mobile devices.
To gain experience and invite use, Novo Nordisk is making the new C4C app free to all patients enrolled in Cornerstones4Care.com and free for download from both the Apple and Google Play App stores. The C4C app represents another milestone in the fast growing Novo Nordisk drive to build its digital health platform, which is being developed in partnership with IBM Watson Health.
Rick Altinger, CEO of Glooko said, "More people than ever are using mobile apps for chronic disease management, and the apps, like the new C4C app, go beyond data capture or tracking to providing insights and recommendations based on that data. By leveraging the expertise and capabilities of Glooko, combined with Cornerstones4Care content, we were able to build a truly unique app to better support people with diabetes." He added, "Ultimately our digital health solution will help health care practitioners gain round-the-clock insight into their patients, and empower people with diabetes to better manage their diabetes, with the aim of ultimately leading to better diabetes management outcomes."
In the United States, more than 29 million people are affected by diabetes. Type 2 diabetes accounts for 90 to 95 percent of all diabetes cases. Diabetes is emerging as one of the most serious health problems of our time; the number of Americans with diabetes has quadrupled over the past 30 years.
About Novo Nordisk
Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: hemophilia, growth disorders and obesity. With U.S. headquarters in Plainsboro, N.J., Novo Nordisk Inc. has nearly 5,000 employees in the United States. For more information, visit novonordisk.us or follow us on Twitter: @novonordiskus.
Glooko is a leading diabetes data management platform and is trusted by many of the world's leaders in diabetes care. Over 1 million people with diabetes and 6,000 health systems in 27 countries use Glooko's FDA-cleared, HIPAA-compliant Mobile, Population Health and Clinic Upload applications with an aim to improve health outcomes for people with diabetes. Glooko syncs with the world's most popular diabetes devices and major fitness and activity trackers and supplies personalized, timely, verified patient data such as blood glucose, food, insulin, blood pressure, diet and weight data.
PRM 0405 Rev A
SOURCE Novo Nordisk
For further information: Further information: Novo Nordisk Media: Susan Jackson (US), +1 609 919 7776, email@example.com; Adam Pittard (Global), +45 3075 5056, firstname.lastname@example.org; Glooko Media: Jennivine Lee Simon, +1 650 720-5310, email@example.com; Novo Nordisk Investors: Kasper Veje (US), +1 609 235 8567, firstname.lastname@example.org; Glooko Investors: Michelle de Haaff (Glooko), +1 650 720 5310, email@example.com